> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel Meeting Nixed on OTC Opioid Reversal Agent
- URL: https://www.fdaweb.com/panel-meeting-nixed-on-otc-opioid-reversal-agent/
- Published: 2023-03-02T12:00:00.000Z
- Updated: 2026-09-14T18:17:59.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153889

*Federal Register* notice: FDA is canceling for undisclosed reasons a 3/20 joint meeting of the Nonprescription Drugs Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee. Panel members were scheduled to discuss a Harm Reduction Therapeutics NDA for naloxone hydrochloride nasal spray, 3 mg/0.1 mL, for proposed nonprescription use as an opioid reversal agent in opioid overdose emergency treatment. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2023-03-02/pdf/2023-04271.pdf?ref=fdaweb.com).